Lead Product(s): RSVDG vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
The vaccine candidate was observed to trigger immunogenicity following nasal administration in healthy adults aged 18 to 50. Investigators also reported the candidate to be safe and well-tolerated.